BioTech

DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children

February 11, 2026 — 04:53 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - DBV Technologies (DBVT) announced that it will present additional data from the positive VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4-7 years at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, in Philadelphia, taking place on February 27- March 2, 2026.

The company plans to submit a BLA to the U.S. FDA in the first half of 2026. The VIASKIN Peanut Patch has already received Breakthrough Therapy Designation, and DBV expects the filing may be eligible for priority review.

The company ended September 30, 2025, with cash of $69.8 million, providing runway into the third quarter of 2026.

The stock has traded between $3.82 to $26.18 over the past year. DBVT closed yesterday's trading at $23.80, up 7.11%, and fell in the pre-market to $22.76, down 4.37%.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech
Stocks Mentioned
DBVT

Latest Articles
Data is currently not available